Skip to main content
. 2022 Apr 5;24:25. doi: 10.1186/s13058-022-01514-2

Fig. 3.

Fig. 3

ANXA1 in 4T1 metastatic mammary cancer cells secretome promotes BV-2 microglial directional migration. ad BV-2 microglial cells were treated with indicated concentrations of a SFM, 4T1 CM or 4T1 ΔANXA1 CM, b recombinant ANXA1 protein, c 4T1 CM supplemented with Boc-MLF FPR1 antagonist or d WRW4 FPR2 antagonist for 24 h in transwell migration assay. Data represent mean ± SEM; n = 3 independent experiments. Images are representative of three independent experiments. ****P < 0.0001